STORE   |   Contact Us   |   Sign In   |   Become Member
News & Press: Radiation News

NExT:Advancing Promising Cancer Therapies from the Lab to the Clinical Trials

Thursday, July 12, 2018  
Share |


NExT: Advancing Promising Cancer Therapies from the Lab to Clinical Trials


At the intersection of the federal government and the private sector lies a unique program called the NCI Experimental Therapeutics (NExT) program. Although NCI operates the program, it runs very much like a small pharmaceutical or biotechnology company, working with external investigators and top scientific experts to advance promising or novel therapies from the earliest stages of research to human clinical trials. Earlier this week, in fact, we were encouraged to see signs of promise from one NExT-developed therapy, when researchers from Duke University reported results from the first human trial of their cancer-killing, or oncolytic, virus therapy in patients with the brain cancer glioblastoma. READ MORE.....

Membership Management Software Powered by YourMembership  ::  Legal